People with chronic wounds deserve more than wound management, they deserve healing.
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue, fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls. Omnio restarts it.
Someone loses a limb due to a chronic wound.
An estimated 167 million people with diabetes will develop diabetic foot ulcers (DFUs), and about one-third of these will become hard-to-heal chronic wounds.
Despite best efforts, standard treatments fall short for hard-to-heal diabetic wounds—contributing to amputation in 1 out of every 5 cases.
Healthcare systems in Europe and the US alone spend over €80-90 billion annually treating chronic wounds.
At the forefront of innovation, Omnio is the first to introduce a next-generation therapy powered by a recombinant plasminogen-based drug: stable, scalable, and regenerative
Early feedback from wound care specialists highlights the potential of Omnio’s recombinant plasminogen in patients with chronic wounds that failed to respond to four weeks of conventional therapy:
"Plasminogen is a novel and vital tool that could change our view on the wound healing process." Due to its upstart and conduct of several functions that is necessary for a regular wound healing process. Once we can observe that it is responsible for a start of the wound healing process we can also expect it to close it in a regulatory way. This wound healing gives us several advantages both to the patient with less pain and odour, and to the caregiver with reliability and trust." Read more
Healing from the Inside Out
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue, fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls. Omnio restarts it.
Omnio’s early internal preclinical data and product design suggest that our recombinant plasminogen has the potential to offer:
65–70% complete healing in early studies
Active against antibiotic-resistant infections (e.g., MRSA)
Reduces pain, inflammation, and amputation risk
Safe, targeted, and easy to administer
Omnio doesn’t just manage wounds. It helps the body heal them.
GMP Manufacturing
Clinical Trial Application for Q4 26
Phase II for Q1 27 — Phase II a
Phase II for Q1 27 — Phase II a
At the core of Omnio’s therapy is plasminogen — a natural protein that helps your body clear damaged tissue, fight infection, and regenerate skin. In people with chronic wounds, that healing process stalls. Omnio restarts it.
Omnio’s early internal preclinical data and product design suggest that our recombinant plasminogen has the potential to offer:
65–70% complete healing in early studies
Active against antibiotic-resistant infections (e.g., MRSA)
Reduces pain, inflammation, and amputation risk
Safe, targeted, and easy to administer
Omnio’s early internal preclinical data and product design suggest that our recombinant plasminogen has the potential to offer:
Scientifically Sound: Omnio’s own studies demonstrate Omnio’s Rec-PLG drug candidate accelerateswound healing and activates defence against infection including antibiotic resistant bacteria.
Manufacturing-ready: Production is being established in line with GMP requirements, scalable, and reproducible
Aligned with human biology: No synthetic growth factors or gene edits
Simple to apply: Subcutaneous injection, no surgery, no complexity
Patients facing chronic diabetic wound ulcers that resist healing — and the clinicians who work relentlessly to make a difference.
Chronic wounds can rob people of mobility, dignity, and independence. Omnio is made for those for which all usual care has failed and are still waiting for a solution. Omnio’s Rec-PLG helps patients regain a normal life and purpose. We begin with diabetic foot ulcers, but our approach applies to a wide range of hard-to-heal wounds.
Chronic wounds should be a thing of the past.
We believe in a future where no one loses their mobility, independence, or quality of life to a wound that won’t heal.
Omnio is working to make that future a reality.By restoring the body’s natural healing process, we’re not just closing wounds, we’re restoring lives.
Whether you’re a clinician, researcher, or investor, we’re building the future of regenerative healing together.
Omnio is ready to scale. We’re looking for partners who believe in better outcomes for patients and are ready to help us bring this therapy to the people who need it most.
info@omnio.se
Uminova Science Park
Tvistevägen 48 SE- 907 19 Umeå Sweden
LinkedIn